Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

Fig. 1

HER2 and VEGFR were overexpressed in OC. A Box plot downloaded from the GEPIA database shows high expression of HER2 in OC tissues. B, D The percentage of HER2 and VEGFR2 expression in 90 OC tumors, categorized into four staining intensities: high, moderate, low, and negative. C, E Representative images of 4 different staining intensities of HER2 and VEGFR2 immunohistochemistry (IHC) on human OC tumor tissue microarrays (TMA). Images were captured at 25 × magnification (upper panels) and 200 × magnification (lower panels), with scale bars = 200 µm (upper panels) and scale bars = 50 µm (lower panels), respectively. F Immunofluorescence was used to analyze the expression of HER2 and VEGFR in two OC PDX tissues. G, H The protein expression levels of HER2 and VEGFR in four OC cell lines and UM-UC-3 cell lines through western blotting (G) and immunofluorescence (H) assay. Immunofluorescence images (F, H) were captured at 400 × magnification, with scale bars = 20 µm

Back to article page